Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Infectious Diseases and Therapy|November 23, 2021
Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission ModelNicolas Voirin, Victor Virlogeux, Clarisse Demont, et al.
Journal of Global Health|October 28, 2020
Incidence of respiratory syncytial virus related health care utilization in the United StatesSabine Tong, Caroline Amand, Alexia Kieffer, et al.
BMC Health Services Research|May 4, 2018
Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008-2014Sabine Tong, Caroline Amand, Alexia Kieffer, et al.
BMC Health Services Research|September 16, 2018
Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008-2014Sabine Tong, Caroline Amand, Alexia Kieffer, et al.
BMC Health Services Research|April 22, 2018
Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysisCaroline Amand, Sabine Tong, Alexia Kieffer, et al.
Human Vaccines & Immunotherapeutics|April 5, 2025
Health economic evaluation of implementing a universal immunization program with nirsevimab compared to standard of care for the prevention of respiratory syncytial virus disease in Canadian infantsThomas Shin, Jason Kh Lee, Alexia Kieffer, et al.
Pharmacoeconomics|February 20, 2025
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant ProtectionFlorian Zeevat, Simon van der Pol, Alexia Kieffer, et al.
Infectious Diseases and Therapy|September 5, 2024
Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related OutcomesAlexia Kieffer, Matthieu Beuvelet, Gerald Moncayo, et al.
Value in Health Regional Issues|April 12, 2019
The Public Health Benefits and Economic Value of Routine Yellow Fever Vaccination in ColombiaAlexia Kieffer, Celine Hoestlandt, Yaneth Gil-Rojas, et al.
Infectious Diseases and Therapy|March 28, 2025
Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in JapanShinichi Noto, Alexia Kieffer, Samira Soudani, et al.
Pageof 3